Design and Synthesis of Prolylcarboxypeptidase (PrCP) Inhibitors To Validate PrCP As A Potential Target for Obesity
作者:Changyou Zhou、Margareta Garcia-Calvo、Shirly Pinto、Matthew Lombardo、Zhe Feng、Kate Bender、KellyAnn D. Pryor、Urmi R. Bhatt、Renee M. Chabin、Wayne M. Geissler、Zhu Shen、Xinchun Tong、Zhoupeng Zhang、Kenny K. Wong、Ranabir Sinha Roy、Kevin T. Chapman、Lihu Yang、Yusheng Xiong
DOI:10.1021/jm101013m
日期:2010.10.14
Prolycarboxypeptidase (PrCP) is a serine protease that may have a role in metabolism regulation. A class of reversible, potent, and selective PrCP inhibitors was developed starting from a mechanism based design for inhibiting this serine protease. Compound 8o inhibits human and mouse PrCP at IC(50) values of 1 and 2 nM and is not active (IC(50) > 25 mu M) against a panel of closely related proteases. It has lower serum binding than its close analogues and is bioavailable in mouse. Subchronic dosing of 8o in PrCP and WT mice at 100 mg/kg for 5 days resulted in a 5% reduction in body weight in WT mice and a reduction in PrCP KO mice.